Table 1.
Peripheral inflammation induces plasma cytokines and chemokines. Plasma was analyzed using a Luminex® 26-plex immunoassay panel for cytokines and chemokines. Peripheral LPS treatment elevated all of the detectable cytokine or chemokine targets assessed at 24h post treatment, regardless of genotype, except for exotoxin, IL-9, IL-13, IL-27, IL-23 and IL-17A. Data represent sample means (SEM) and were analyzed using a two-ANOVA followed by the Holm-Sidak method for pairwise multiple comparisons. n = 6–9 samples/group.
| Genotype | Main Effects | Interaction | ||||||
|---|---|---|---|---|---|---|---|---|
| Protein Target (pg/mL) | BDNF+/+ | BDNF+/− | Treatment | Genotype | Treatment × Genotype | |||
| Saline | LPS | Saline | LPS | p-value | p-value | |||
| Cytokines | IL-10 | 0.34 (0.2) | 9.23 (2.5) | 0.15 (0.1) | 9.58 (2.7) | p<0.001 | n.s. | n.s. |
| IL-1 β | 0.20 (0.l) | 0.91 (01) | 0.080 (0.05) | 1.15 (0.3) | p< 0.001 | n.s. | n.s. | |
| IL-5 | 4.50 (0.7) | 26.66 (9.5) | 3.91 (1.3) | 14.72 (5.3) | p<0.01 | n.s. | n.s. | |
| IL-6 | 8.62 (2.0) | 161.90 (76.2) | 4.43 (11) | 147.31 (72.0) | p<0.01 | n.s. | n.s. | |
| IL-22 | 17.65 (3.4) | 89.04 (28.7) | 23.24 (5.5) | 272.23 (137.4) | p<0.01 | n.s. | n.s. | |
| TNFα | 1.99 (0.2) | 5.73 (1–1) | 1.85 (0.2) | 7.79 (2.1) | p<0.001 | n.s. | n.s. | |
| IL-18 | 247.07 (38.8) | 1679.50 (331.8)*** | 170.25 (43.0) | 2805.17 (428.4)### +++ | p<0.001 | p<0.05 | p<0.05 | |
| Chemokines | IP-10 | 12.74 (13) | 79.82 (8.0) | 14.41 (1.5) | 93.96 (14.5) | p<0.001 | n.s. | n.s. |
| GROα | 9.08 (5.8) | 31.23 (12.9) | 7.35 (3.0) | 36.35 (10.6) | p<0.01 | n.s. | n.s. | |
| RANTES | 40.82 (10.7) | 619.38 (150.1) | 56.52 (13.6) | 552.39 (209.4) | p< 0.001 | n.s. | n.s. | |
| MIP-1α | 1.21 (0.3) | 5.75 (0–9) | 1.99 (0.8) | 5.33 (0.9) | p<0.001 | n.s. | n.s. | |
| MCP-3 | 47.04 (6.3) | 537.43 (124) | 54.01 (3.2) | 562.74 (23.6) | p<0.001 | n.s. | n.s. | |
| MCP-1 | 19.27 (2.5) | 248.2 (49.7) | 18.01 (1.9) | 379.02 (82.2) | p<0.001 | n.s. | n.s. | |
| MIP-2 | 6.86 (0.4) | 21.55 (3.2) | 7.30 (0.5) | 24.60 (4.7) | p<0.001 | n.s. | n.s. | |
| MIP-1 β | 0.25 (0.08) | 4.97 (12) | 0.42 (0.1) | 3.91 (0.8) | p<0.001 | n.s. | n.s. | |
= main effect (treatment or genotype)
= post-hoc comparison between saline and LPS within the same genotype (BDNF+/+ or BDNF+/−)
= post-hoc comparison between BDNF+/+ and BDNF+/− with the same treatment (saline or LPS)
p<0.05–0.01
p<0.01–0.001
p<0.001